Modules, networks and systems medicine for understanding disease and aiding diagnosis by Gustafsson, M. et al.
Gustafsson et al. Genome Medicine 2014, 6:82
http://genomemedicine.com/content/6/10/82REVIEWModules, networks and systems medicine for
understanding disease and aiding diagnosis
Mika Gustafsson1†, Colm E Nestor1†, Huan Zhang1†, Albert-László Barabási2, Sergio Baranzini3, Sören Brunak4,5,
Kian Fan Chung6, Howard J Federoff7, Anne-Claude Gavin8, Richard R Meehan9, Paola Picotti10, Miguel Àngel Pujana11,
Nikolaus Rajewsky12, Kenneth GC Smith13,14, Peter J Sterk15, Pablo Villoslada16 and Mikael Benson1*Abstract
Many common diseases, such as asthma, diabetes or
obesity, involve altered interactions between thousands
of genes. High-throughput techniques (omics) allow
identification of such genes and their products, but
functional understanding is a formidable challenge.
Network-based analyses of omics data have identified
modules of disease-associated genes that have been
used to obtain both a systems level and a molecular
understanding of disease mechanisms. For example,
in allergy a module was used to find a novel candidate
gene that was validated by functional and clinical
studies. Such analyses play important roles in systems
medicine. This is an emerging discipline that aims to
gain a translational understanding of the complex
mechanisms underlying common diseases. In this
review, we will explain and provide examples of how
network-based analyses of omics data, in combination
with functional and clinical studies, are aiding our
understanding of disease, as well as helping to prioritize
diagnostic markers or therapeutic candidate genes. Such
analyses involve significant problems and limitations,
which will be discussed. We also highlight the steps
needed for clinical implementation.are already being used in the clinic to predict disease
or personalize treatment and examples include BRCAThe complexity of common disease
Despite impressive advances during the past century,
modern health care is faced with enormous challenges.
One problem is that currently available drugs show
highly variable clinical efficacy, which results not only in
suffering, but also contributes to increasing costs. The
annual cost of ineffective drugs in the US alone is* Correspondence: mikael.benson@liu.se
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org/publicdomain/zero/1.0/) applies to the dataestimated at US$350 billion [1]. Variable efficacy also
adds to the huge costs associated with drug discovery,
development and clinical trials (on average US$1 billion
per drug), which further impacts the financing of health
care. These problems reflect the complexity of common
diseases, which can involve altered interactions between
thousands of genes. Because of the large number of
genes and their interconnection, it is very difficult to
gain functional understanding of disease mechanisms by
detailed studies of individual genes.
This problem of complexity is compounded by disease
heterogeneity: patients with similar clinical manifestations
may have different underlying disease mechanisms. Asthma
is an example of such a disease; it can be caused by in-
fection, allergens or other environmental factors, which
give rise to different inflammatory responses (Figure 1).
Variations in response may underlie the observation
that between 10 and 20% of patients do not respond to
one of the most common asthma drugs, corticosteroids
[2]. This variation, however, can potentially be exploited
to find novel drugs for nonresponders in asthma, allergy
and other diseases, as well as to identify patients that re-
quire such drugs [3].
Despite the success of single diagnostic markers, there
is a pressing need for multiple markers. Single markers
genotyping in breast cancer, CCR5 mutation status in
HIV infection and newborn screening for metabolic de-
fects [4]. Recently, optimization of the anticoagulant
therapy warfarin based on genotyping of two genes was
described [5]. However, the diagnostic accuracy of indi-
vidual or pairs of biomarkers is likely to be limited as
only a fraction of disease-associated genes is predicted
to have a large effect on any specific disease; most
disease-associated genes have small effects [6]. Yet, thetral Ltd. The licensee has exclusive rights to distribute this article, in any medium,
is time, the article is available under the terms of the Creative Commons Attribution
y/4.0), which permits unrestricted use, distribution, and reproduction in any medium,
The Creative Commons Public Domain Dedication waiver (http://creativecommons.
made available in this article, unless otherwise stated.
Multiple causes
Multiple, overlapping disease mechanisms
Single clinical phenotype
Asthma
Allergens Microbes Environment
Figure 1 A single disease phenotype can be caused by multiple
mechanisms. As an example, asthma can be triggered by allergens,
microbes and other environmental factors, each of which may
activate different disease mechanisms, which are depicted as shared
(black) and specific (red) networks.
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Thus, the accuracy of a biomarker based on a large-
effect gene may vary depending not only on variations in
that gene, but also on variations in the many genes with
small effects.
Systems medicine is an emerging discipline that aims
to address the problem that a disease is rarely caused by
malfunction of one individual gene product, but instead
depends on multiple gene products that interact in a
complex network [7]. Here, we explain how and why
systems medicine, and specifically network approaches,
can be used to assist clinical decision making and to
identify underlying disease mechanisms. We focus on the
use of disease modules to uncover pathogenic mecha-
nisms and describe how these can be extended into multi-
layer networks. We finish by discussing the current
problems and limitations of network and systems ap-
proaches and suggest possible solutions. We also highlight
the necessary steps for clinical implementation. We focus
on systems medicine as a network-based approach to ana-
lysis of high-throughput and routine clinical data to pre-
dict disease mechanisms to diagnoses and treatments.Systems and network medicine to support clinical
decision-making
Similar to many evolving medical disciplines, there is no
generally accepted definition of systems medicine, al-
though different proposals are available [8,9]. Some view
it as an interdisciplinary approach that integrates re-
search data and clinical practice and others view it as
fusion of systems biology and bioinformatics with a
focus on disease and the clinic. Recent articles have de-
scribed systems medicine as a high-precision, mathemat-
ical model of variables from different genomic layers
that relate to clinical outcomes such as treatment re-
sponse [10,11]. Rather than trying to distinguish between
systems medicine and other disciplines, our review is
based on the premise that systems medicine is a natural
extension of, or is complementary to, current models for
clinical decision-making.
In general, clinical decisions are based on a diagnostic
model consisting of multilayered pattern recognition of
multiple data inputs linked to scientific reasoning about
causality. This diagnostic model can be exemplified by
pneumonia. On a phenotypic level, pneumonia is often
characterized by fever and symptoms or signs of changes
in the respiratory tract. This layer of information can be
linked to data (such as radiographic imaging, laboratory
tests for inflammatory signs of infection and microbial
tests) that suggest the cause of the disease. The phys-
ician may need to take into account other layers, includ-
ing socioeconomic and environmental factors. For
example, if the patient is homeless and a smoker, this is
likely to affect diagnosis, treatment and the innate im-
mune response of the patient to the infection. Thus, in
the case of pneumonia, accurate diagnostic decisions
can be made by pattern recognition and reasoning.
However, for many diseases, diagnosis is more difficult.
The external causes, disease mechanisms or the involve-
ment of cells, tissues or organs may be highly complex
or only partially known. In such cases, the physician
would be helped by a formal diagnostic model that gave
decisional support by presenting the variables so that
contributory disease mechanisms can be elucidated and
diagnostic predictions computed. One approach is to
use a template in which omics clinical variables are orga-
nized into a network to understand disease mechanisms
and make diagnostic predictions. Such a template would
naturally build on the current diagnostic model of pat-
tern recognition. Using this diagnostic model would
allow different clinical variables, such as symptoms and
laboratory variables, to be described in different network
layers. In this way, multilayer network models can be
constructed that include all known relevant variables,
ranging from genetic variants to environmental factors.
In summary, the potential advantage of a multilayer
network model is that it provides a framework in which
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taneously, thereby informing and improving the deci-
sional pathway of medical professionals and patients
[12]. Before we look at how networks and modules can
be used to uncover disease mechanisms, we first provide
an overview of networks in biology.
A brief introduction to networks
Networks provide graphical representations of complex
systems. In the context of cellular networks, molecules
such as genes and proteins are represented as nodes,
and the interactions among them as links. In a landmark
article in 1999, it was shown that networks in techno-
logical, social and biological systems have common
designs that are governed by simple and quantifiable or-
ganizing principles [13]. Key findings were that a frac-
tion of the nodes serve as hubs with multiple links,
whereas the vast majority of nodes have few links. The
hubs often have large individual effects, in contrast to
the nodes with few links. The hubs contribute to the
small world property of networks: all nodes in a network
are generally connected by a limited number of links.
Another important characteristic is that functionally
related nodes tend to be highly interconnected and
co-localize in networks, thereby forming modules
[7,14] (Table 1).
In the context of disease, disease-associated genes
identified by omics studies can be computationally
mapped on to models of the human protein-protein
interaction (PPI) network. In other words, each disease-
associated gene is mapped on to its matching protein
product. The resulting maps have characteristics that are
similar to those found in other types of networks. One
of the most important characteristics is that functionally
related genes tend to co-localize and form disease
modules.
Disease modules for understanding pathogenic
mechanisms
Disease modules can help to organize and prioritize
disease-associated genes identified by high-throughputTable 1 Glossary of terms
Term Description
Network A graphical representation of a complex system. For
example, in a protein network, proteins are nodes, and
interacting proteins are linked by edges
Disease
module
When mapped onto the protein-protein interaction
network, disease-associated genes tend to co-localize and
form networks of functionally related genes. These networks
are referred to as disease modules
Multilayer
disease
A module whose nodes and edges are located across
different layers of disease-relevant information. Such layers
could include transcription factor networks,
genetic variants and even environmental factorsanalyses (Figure 2), as well as to provide an overview of
disease mechanisms by performing pathway analyses.
Disease modules can also help to identify novel disease
genes, biomarkers or therapeutic targets. Remarkably,
one landmark study for systems medicine was initiated
by researchers without a clinical background, who had
studied network design principles in model organisms
like yeast cells or worms [15]. In 2007, Pujana et al. [16]
described a module relevant to breast cancer, and identi-
fied a novel candidate gene, HMMR, that was validated
by functional and genetic studies. Several module-based
studies have been performed in other diseases, including
cancer [17-20], neurological [21-23], cardiovascular [24],
and inflammatory diseases [25-27]. One of the studies
showed how protein interaction modules could be used
to predict outcome in breast cancer [20]. In a study of
autoimmune diseases, mRNA modules were used to pre-
dict disease progression based on functional studies of
underlying mechanisms [28]. In 2014, a module-based
approach for drug discovery was described in rheuma-
toid arthritis based on a meta-analysis of genome-wide
association studies (GWASs) of 100,000 subjects [29].
Analysis of disease modules exploits the general prin-
ciples of networks, such as alteration of hub genes being
likely to have large effects, while alterations in the many
genes with few links will likely correspond to small-
effect genes. Thus, specific therapeutic targeting of a
hub gene is more likely to be effective than targeting a
gene with few interactions. Indeed, genes targeted by
drugs have more interactions than other genes [30],
which increases the risk that a drug targeting a specific
disease gene may have an off-target effect [31]. An im-
portant observation is that nodes that are highly inter-
connected in a network are likely to be functionally
related. Thus, novel candidate genes can be found
among the interactors of known disease genes [32].
One recent example of a successful module-based ap-
proach was based on the assumption that the genes in a
module would be co-regulated by the same set of tran-
scription factors (TFs) that regulate a known disease
gene, IL13 [33] (Figure 3). Twenty-five putative IL13-
regulating TFs were knocked down using short interfer-
ing RNA (siRNA), of which seven were found to affect
IL13. The knockdowns were repeated for these TFs,
followed by mRNA microarrays to detect their down-
stream targets. This led to the identification of a module
of highly interconnected genes. That module contained
several genes of known relevance to allergy, such as
IFNG, IL12, IL4, IL5, IL13 and their receptors. It also
contained novel candidate genes, including S100A4,
which was validated as a diagnostic and therapeutic
candidate by a combination of functional, mouse and
clinical studies. A mouse knock-out model showed that
S100A4 had extensive phenotypic, cellular and humoral
S100A4
IL13
(a) (b)
Figure 2 A disease module. (a) Conceptual model of how disease-associated genes (blue nodes), identified by high-throughput analysis, tend to
co-localize in the human protein-protein interaction network (white nodes), forming a module (blue oval). The genes in the module are assumed to be
more important for the disease than extramodular genes. (b) An actual disease module from allergic patients, showing extracellular proteins that were
putatively co-regulated with IL13. Blue nodes are associated with cytokine activity, purple nodes are associated with hormone activity, and orange
nodes are associated with growth factor activity according to Gene Ontology Molecular Function. The diagram in (b) is reproduced, with permission,
from Bruhn et al. Science Translational Medicine 2014 [33].
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tial was demonstrated by treatment with a specific anti-
body, both in the mouse model and in cells from allergic
patients.
Multilayer disease modules
The success of single module approaches in identifying
candidate genes prompted researchers to extend it to
multiple modules to link genomic, phenotypic and envir-
onmental variables together. Rapid development of high-
throughput techniques has enabled global analyses of
different network layers ranging from DNA to proteins,
as well as metabolites and lipids [34,35]. Similar to
genes, the variables in each layer can be linked to each
other. Consider, for example, one disease module formed
by mRNAs and another from single nucleotide polymor-
phisms (SNPs). If an mRNA and a SNP in each module
map to the same protein, they can be linked. This
principle can be expanded to all proteins in the module
and the overlap tested statistically. Another example is
modules formed by genes and their regulators, such as
TFs or microRNAs. Genes can be linked if they are
regulated by the same microRNAs, and a double-layer
module can then be formed by linking microRNAs that
regulate the same gene. By combining different high-
throughput analyses it is therefore possible to form
multilayer disease modules (MLDMs).
Multidimensional models can be used to form rejectable
hypotheses of how genes, gene products and regulators
interact with each other. For example, does a disease-
associated SNP in a promoter region of a module gene
change the expression of that gene? Does a microRNA
regulate its predicted target genes in a module? The clinicalrelevance of MLDMs lies in that they can provide a
framework to identify optimal combinations of diagnos-
tic markers from different layers, based on functional
understanding of the pathogenic roles of those markers.
For example, microRNAs and genetic variants have
been used to examine disease-associated variations in
mRNA expression in gliomas, and to predict disease
outcome [36,37]. In allergy, functional studies showed
that mRNA modules were co-regulated by microRNAs,
some of which had hub-like functions and potential
diagnostic relevance [38].
An important aspect of MLDMs is that they can be
linked to modules formed by other clinical data. For ex-
ample, a link can be placed between a disease and a gene
associated with that disease [39]. Next, diseases that are
associated with the same gene can be linked and form a
human disease network. The same principle can be ap-
plied to the disease genes forming a disease gene net-
work. Such networks are modular and can be linked, so
that diseases can be associated with the underlying dis-
ease mechanisms. It is also possible to construct and link
modules containing other relevant data, such as social
and environmental factors (Figure 4). It is of note that
the construction of MLDMs is complicated by several
technological limitations, which are discussed later in
this review.
MLDMs might also be useful for tracking disease over
multiple time points. Diseases are dynamic processes
rather than static entities, and the underlying processes
and time frames may range from hours in rapidly evolv-
ing cases, such as meningitis, to decades in cancer.
Disease progression is perhaps best understood in can-
cer. For example, at a molecular level, a study of chronic
GEM of allergen-
challenged T cells
Sequence-based
predictions Literature
25 IL13 regulating transcription factors (TFs) 
Diagnostic and therapeutic
studies in allergic patients
Functional and therapeutic
studies in mouse models 
Module
genes
Allergic
patients
S100A4
High-throughput RNAi screen of TFs in
human CD4+ T cells using IL13 as read-out
Knock-down of positively screened TFs and
known IL13 regulators with microarray analysis
and construction of a gene module
A significant part of the module genes
were differentially expressed in 
allergen-challenged T cells from patients
(a)
(b)
(c)
(d)
Figure 3 A module-based approach to identify disease-relevant
diagnostic and therapeutic candidate genes in allergy. (a)
Twenty-five putative IL13-regulating transcription factors (TFs) were
identified by combining data from mRNA microarrays, sequence-based
predictions and the literature. (b) IL13-regulating TFs were validated by
siRNA-mediated knockdown of the 25 TFs in human total CD4+ T cells
polarized toward TH2 using IL13 as a read-out. The target genes of the
TFs were identified by combined siRNA knockdown of the positively
screened TFs/known IL13-regulating TFs from literature and microarray
analyses. This resulted in a module of genes that was co-regulated
with IL13 in TH2-polarized cells and significantly overlapped with
differentially expressed genes from allergen-challenged T cells from
allergic patients. For further validation experiments, the study focused
on module genes that encoded secreted proteins and had not been
previously associated with allergy. (c) Functional, diagnostic and
therapeutic studies involving one of the module genes, S100A4, were
performed in patients with seasonal allergic rhinitis, allergic dermatitis
and a mouse model of allergy. (d) Model of S100A4-induced disease
mechanisms. Allergic inflammation requires the sensitization of the
immune system by allergens, resulting in the production of
antigen-specific T cells. The interaction of dendritic cells (DC) in
the draining lymph node with T cells is a critical step that is
dependent on S100A4. B-cell maturation as a result of T cell-B cell
crosstalk (for example, the release of TH2 cytokines by T cells)
leads to the production of IgE and IgG1 by plasma cells. Cytokines
and chemokines released by T cells stimulate the migration of
circulating granulocytes (for example, neutrophils and eosinophils) to
the inflammatory site (skin). Differentiation of naïve T cells into CD8+
cytotoxic T cells will exacerbate the skin damage. Blue arrows indicate
the flow of the allergic responses. Green arrows indicate the promotion
of these processes by S100A4. GEM, gene expression microarray.
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stantial genetic heterogeneity of tumor cells from the
same patients over time [40]. Such developments were
linked to disease deterioration and variable treatment
response. In breast cancer, module kinetics has been
directly linked to treatment response; in a subset of pa-
tients, treatment with one drug rewired the disease mod-
ule so that it became sensitive to another drug [41].
Thus, understanding of module kinetics can be exploited
for sequential treatment with different drugs. Ideally, this
principle should be expanded so that all diseases are
staged using MLDMs with omics and routine clinical
data integrated. In the future, it may be possible to infer
early MLDMs, before patients become symptomatic,
allowing preventative medicine.
It is possible that personal MLDMs could become a
cornerstone for health care, and could be used for the
early diagnosis of changes in module function, based on
functional understanding of why disease-causing nodes
in the MLDMs change (such as due to a genetic variant).
As the bioinformatics principles for analyzing different
forms of variables are largely the same, MLDMs could
also include other forms of clinical information, such as
routine laboratory tests and medical imaging. The versatil-
ity and resolution of medical imaging is steadily increasing
and is aiming to provide functional understanding of
PPI network
Symptoms and signs network
Environmental network
from different layers
mRNA
Protein
SNPs
Mutations
Epigenetics
(a) Network construction (b) Disease MLDM (c) Predictive markers (d) Personalized treatment
nc-RNA
Spirometry,
skin prick test,
etc.
Social factors
Pollen,
microbes,
etc.
Figure 4 An idealized systems medical approach to personalized treatment. (a) All factors that influence a disease can potentially be
described by networks. For example, symptoms and signs that tend to co-occur can be linked and form a module that corresponds to a disease
(pink oval). That module may be linked to underlying modular protein changes (blue oval). Similarly, the disease module may be linked to co-occurring
environmental factors (green oval). (b) Each of the modules in (a) can be further divided to represent different sublayers, from which (c) predictive
markers from the different sublayers can be identified, and used for (d) personalized treatment. MLDM, multilayer disease module; nc-RNA, noncoding
RNA; PPI, protein-protein interaction; SNPs, single-nucleotide polymorphisms.
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would allow, for example, specific traits imaged in liver
cancer to be linked to prognostic gene expression changes
[42]. Similarly, obesity traits could be linked to molecular
changes [43].
In summary, MLDMs can potentially be used as tem-
plates to integrate and analyze multiple layers of disease-
relevant information. Similar to the current diagnostic
model discussed above, analyses can be based on func-
tional understanding, but with higher resolution and the
option for computational predictions. When the under-
lying mechanisms are revealed, our view of various com-
mon diseases might alter, prompting reclassification of
multiple diseases.
Networks to reclassify diseases based on
pathogenic mechanisms
The current diagnostic classification is based on obser-
vations of symptoms and signs, associations with exter-
nal factors (for example, pollen and allergy), and use of
diagnostic aids like radiology, and variable molecular
knowledge of disease mechanisms. A fundamental
problem with this classification system is that the same
phenotype may result from multiple disease mecha-
nisms. Thus, if a drug is only effective against one of
those mechanisms, its use in patients with differentunderlying mechanisms will not be therapeutically
successful.
Ideally, diagnoses should be based on accurately linking
phenotypes with all possible underlying mechanisms. Tak-
ing this idea to its extreme would require simultaneously
analyzing all possible external causes and mechanisms.
Since there is considerable comorbidity, all diseases should
also be simultaneously analyzed. Actually, the first steps in
this direction have been already taken, using network-
based analyses of public databases and high-throughput
data. In a landmark study, Goh et al. [44] mapped human
disease genes onto the interactome, and found that genes
associated with phenotypically similar diseases tended to
co-localize. Similar observations were made for networks
derived from expression profiling [45]. This led Barrenas
et al. [39] to construct a module-based map of human
diseases. Similar to a geographical map, different disease
categories should co-localize in different parts of the in-
teractome (Figure 5a). Ideally, such a map could be used
as a reference to improve diagnostic accuracy and clas-
sification, and better identify diagnostic and therapeutic
candidates. However, despite the diseases being very
diverse (including metabolic, inflammatory and onco-
logical diseases), they partially overlapped. Thus, instead
of being dispersed in the interactome, the disease mod-
ules formed a flower-like structure (Figure 5b). The
(a) Dispersed disease modules (b) Overlapping disease modules
Figure 5 Relationship between different disease modules on the protein-protein interaction network. (a) A hypothetical model of
three different diseases mapped on the human protein-protein interaction network. The modules are dispersed in the network. (b) Instead,
meta-analysis of mRNA microarray and genome-wide association study data show that disease modules partially overlap and form a shared
module (grey) [39]. The shared module has important pathogenic, diagnostic and therapeutic implications.
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module with remarkable characteristics. It was enriched
for inflammatory, metabolic and proliferative pathways.
Since these pathways have key roles in survival, this led
to the hypothesis that altered function in one of the
pathways may spill over to the others and cause one or
more diseases. Indeed, meta-analysis of GWASs repre-
senting more than 100 diseases and hundreds of thou-
sands of patients showed that the shared module was
highly enriched for SNPs from these diseases [39].
These findings contrast with the dogma that diseases
are mainly caused by disease-specific genes, and that
nonspecific genes are secondary or irrelevant. Further
studies showed that the shared module was more
enriched for GWAS genes than disease-specific genes.
Moreover, it was highly enriched for known biomarkers
and therapeutic targets. Clinical studies showed that
the expression profile of the shared module had the
potential to stratify allergic patients for treatment with
corticosteroids. Because the shared module was highly
enriched for GWAS genes it is likely that it has an im-
portant causal role, which has diagnostic implications
for predictive and preventative medicine [3,39].
Other approaches to disease reclassification have in-
volved mining of electronic health records to search for
comorbidity patterns and underlying genetic variants
[46-51]. For example, by combining electronic health re-
cords and GWASs, Denny et al. [46] showed novel asso-
ciations. For example, the presence of polymorphisms in
IRF4 was linked to skin cancer and actinic keratosis [46].
There are also enormous resources of biomedical rele-
vance available in the public domain that can be analyzed
with network-based principles. For example, Medline con-
tains some 20 million abstracts, the Gene Expression
Omnibus one million expression experiments, and the
Encyclopedia of DNA Elements (ENCODE) more than2,500 high-throughput experiments. In one study, new
indications for known drugs were predicted based on inte-
gration of public expression data of more than 100 dis-
eases and expression data from the drugs. For example, an
antiulcer drug, cimetidine, was shown to be a therapeutic
candidate in lung cancer [52]. In another study, a hypoth-
esis about T-cell differentiation was tested completely in
silico, by mining and modeling data in the public domain.
All abstracts in MedLine were mined to construct a mod-
ule relevant for T-cell differentiation. This module was
tested by simulated activation and knockdown of individ-
ual module genes. The simulation yielded unexpected
results, which were validated by analyses of correlation
patterns in public mRNA microarray data from different
T-cell-associated diseases [53]. It is likely that network-
based analysis of highly diverse data sets with increasingly
powerful computational tools will contribute to a new dis-
ease taxonomy. Already, there are examples of this, such
as in severe asthma [54].
Problems, limitations and opportunities
Every step of a systems medicine study, including
the use of network and module approaches, involves
problems and limitations. One problem is that high-
throughput analyses often require large sample sizes to
obtain statistically significant results, and sufficient
samples may be difficult to obtain. In some diseases, it
is difficult or impossible to obtain relevant clinical
samples, such as neurodegenerative diseases. One solu-
tion to this problem, at this stage, may be to focus on
particularly tractable diseases. As an example, in sea-
sonal allergic rhinitis, the key external trigger (pollen)
and the key cell type (lymphocytes) are both known
and readily accessible. The disease occurs at a known
time point each year. Thus, it is possible to mimic the
disease process by in vitro challenge of T cells from
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to perform functional studies of candidate genes in
activated T cells, or in a well-defined mouse model of
allergy. The disease process and diagnostic markers
can be analyzed locally in the affected organ [33].
Another issue is that many different cell types are
often involved in one disease, and more than one may
be important. The involvement of multiple cell types in
the development of a disease introduces an additional
challenge to the generation of meaningful MLDMs
from omics data relying on cell mixtures. This may be
addressed in the near future by the application of
single-cell analysis technologies. Recent developments
in sequencing allow determination of single-cell ge-
nomes and transcriptomes [55,56], while mass cytome-
try enables the targeted quantification of proteins and
their modifications in different cells from a heteroge-
neous population [57].
Other challenges arise from technical problems, which
include variation in the accuracy and sensitivity of high-
throughput techniques. This is particularly so for global
protein profiling, which is complex and difficult to per-
form in a clinical setting. The occurrence in a proteome
of various post-translational modifications, SNPs and
alternative splicing of proteins further complicates such
analyses. However, recent technological advances indi-
cate that targeted proteomics may partly address these
limitations and render the analysis of predetermined
sets of proteins over large numbers of samples [58,59].
Targeted protein assays may also enable the quantifica-
tion of highly homologous protein sequences, such as
splice variants, protein isoforms and mutated versions of
a protein [60], in a clinical laboratory setting. Another
emerging targeted proteomic application is the gener-
ation of perpetually reusable digitalized maps of the
proteomic signals of a sample [61]. The thus generated
maps can then be mined using targeted data extraction
strategies to quantify disease-related proteins of interest
over large cohorts of patient samples. Literature know-
ledge and MLDM layers that are more easily measured
than proteins, such as mRNA or genomic information,
could help to identify proteins for such targeted ana-
lyses [62]. Similarly, recent technical advances may
help to include targeted metabolites and lipids in the
MLDMs [63,64].
The bioinformatics analyses involve several problems
of their own. For example, important limitations of PPI
networks are that they are generally not cell specific, and
are constructed based on heterogeneous sources such as
literature and databases, experimental data, inferences
from high-throughput studies, or computational predic-
tions [65].
A key remaining problem is how to validate results from
analyses involving thousands of genes or gene products.Systems medicine is based on combining genome-scale
validation strategies with detailed studies of individual fac-
tors. Therefore, it is mandatory to follow recommenda-
tions for multiscale analysis [66], thereby strictly limiting
false discovery [67]. Recently, these analyses have been an-
chored to MLDMs, by providing stepwise criteria for the
use of omics-based predictors in clinical trials [68].
On a genomic scale, an important validation principle
is to test for genomic concordance. In other words, to
test if there is concordance between different layers in
an MLDM. For example, it is possible to validate by
examining if disease modules that are derived from
mRNA microarray analyses are enriched for SNPs iden-
tified by independent GWASs of the same diseases.
Another form of genome-scale validation is to examine
if siRNA-mediated knockdowns of predicted upstream
genes in a module result in altered expression of down-
stream module genes. If these two genome-scale ana-
lyses support the findings, then detailed functional and
clinical studies can be performed, including mouse dis-
ease models [33].
Clinical implementation of systems and network
medicine
There are already examples of gene testing being used in
the clinic. Diagnostic products to stratify breast cancer
based on gene expression profiling are commercially
available, such as the MammaPrint [69]. MLDMs could
also be used to stratify patients for individualized medi-
cine based on functional understanding of why patients
do or do not respond to a particular drug. This could, in
turn, lead to development of novel drugs for nonre-
sponders, directed against mechanisms not targeted by
existing drugs. MLDMs could also be used for reposi-
tioning of drugs that have not reached the market be-
cause of low efficacy or side effects.
The clinical implementation of systems medicine
would require extensive clinical, administrative and edu-
cational adaptations. One current problem is that very
few clinicians are involved in systems medical research,
education or implementation. Yet, systems medicine is
beginning to become a part of the curricula of many
medical schools (for example, http://gumc.georgetown.
edu/spi/systemsmedicine).
The European Commission has launched a project aim-
ing to draw up a road map for the clinical implementation
of systems medicine (https://www.casym.eu). This road
map is based on integrating the views from different rele-
vant stakeholders, including clinicians, basic researchers,
representatives of the pharmaceutical industry, funding
bodies and government health agencies. Educational pro-
grams for the training of health professionals at different
stages of their careers, starting from medical school, have
already started in the USA and some European countries.
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ciples are in line with clinical reasoning, and perhaps
can be seen as a natural extension that permits formal-
ized reasoning about pathogenic mechanisms, as well as
diagnostic predictions.
Conclusions and future directions
Many of the main challenges facing modern health care
arise from the complex and heterogeneous characteris-
tics of common diseases. The same phenotype may re-
sult from different mechanisms, and each mechanism
will require a different treatment. Ideally as many pheno-
types, genes and other disease-associated variables as
possible should be studied together in order to reclassify
diseases based on functional understanding of underlying
mechanisms. However, this involves multiple, large-scale
methodological, economical and ethical challenges, which
are only partially resolved.
The rapid development of systems medicine is illus-
trated by a prospective study of 100 healthy subjects,
known as the Hundred Person Wellness Project, which
was started in March 2014. Blood, urine and stool sam-
ples will be regularly analyzed for multiple biomarkers
or microbes, and participants will wear digital devices
that monitor physical activity, sleep patterns and blood
pressure. The aim is to predict and prevent disease. If
successful, the study will expand to include 100,000 sub-
jects [70].
The study suggests that the predictive and personal-
ized medicine based on MLDMs will become a reality.
From an idealized perspective, a global description of
MLDMs for all diseases and relevant cell types would
lead to increased understanding of the relationships be-
tween pathogenic mechanisms and disease phenotypes.
This would include understanding of comorbidity and
subgroups. An important clinical use would be diagnos-
tic reclassification of diseases, which in turn could con-
tribute to more effective diagnosis, drug development
and treatment. The next natural aim would be to include
a time axis in the reclassified diagnostic disease map. In
such a map, diseases should be staged by defining
MLDMs at different time points. Ideally, such staging
should extend to early and even presymptomatic stages.
If so, this could help to identify markers that aid in the pre-
diction and perhaps prevention of disease before it becomes
symptomatic. The identification of early and presymptom-
atic MLDMs based on clinical data would be a very large
undertaking that would require population-based studies
where the subjects are followed for several years. Alterna-
tively, it could be possible to infer early MLDMs based on
analyses of animal models of diseases or in human cells
exposed to known external disease triggers, such as T cells
exposed to allergen. The clinical advantages of predictive
and preventative medicine can be exemplified by earlytreatment of rheumatoid arthritis and multiple sclerosis,
which reduces the risk of debilitating disease [71]. If these
examples can be generalized, medicine would be likely to
change from reactive to proactive.
Clinical research is rapidly entering the era of low-cost
personalized omics, and we believe that systems medi-
cine is ideally placed to make sense of this sea of com-
plex data, resulting in tangible improvements in patient
care and treatment.
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